S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
Text released of 99-page bill to raise debt limit, curb spending; lawmakers to review as House eyes Wednesday vote
Lithium Has Boomed And This American Stock Is Ready.. (Ad)
Stock market today: Asian markets mostly higher after Biden-McCarthy deal on US debt
PwC Australia sidelines 9 directors as leak of tax information investigated
This NASDAQ Stock Is The Amazon Of Medical Supply (Ad)
North Korea notifies neighboring Japan it plans to launch satellite in coming days
Drought-struck Barcelona quenches thirst with costly desalination
Lithium Has Boomed And This American Stock Is Ready.. (Ad)
Takeaways on debt ceiling: McCarthy's balancing act, Biden's choice and the challenges ahead
Debt ceiling agreement gets thumbs up from business groups, jeers from some on political right
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
Text released of 99-page bill to raise debt limit, curb spending; lawmakers to review as House eyes Wednesday vote
Lithium Has Boomed And This American Stock Is Ready.. (Ad)
Stock market today: Asian markets mostly higher after Biden-McCarthy deal on US debt
PwC Australia sidelines 9 directors as leak of tax information investigated
This NASDAQ Stock Is The Amazon Of Medical Supply (Ad)
North Korea notifies neighboring Japan it plans to launch satellite in coming days
Drought-struck Barcelona quenches thirst with costly desalination
Lithium Has Boomed And This American Stock Is Ready.. (Ad)
Takeaways on debt ceiling: McCarthy's balancing act, Biden's choice and the challenges ahead
Debt ceiling agreement gets thumbs up from business groups, jeers from some on political right
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
Text released of 99-page bill to raise debt limit, curb spending; lawmakers to review as House eyes Wednesday vote
Lithium Has Boomed And This American Stock Is Ready.. (Ad)
Stock market today: Asian markets mostly higher after Biden-McCarthy deal on US debt
PwC Australia sidelines 9 directors as leak of tax information investigated
This NASDAQ Stock Is The Amazon Of Medical Supply (Ad)
North Korea notifies neighboring Japan it plans to launch satellite in coming days
Drought-struck Barcelona quenches thirst with costly desalination
Lithium Has Boomed And This American Stock Is Ready.. (Ad)
Takeaways on debt ceiling: McCarthy's balancing act, Biden's choice and the challenges ahead
Debt ceiling agreement gets thumbs up from business groups, jeers from some on political right
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
Text released of 99-page bill to raise debt limit, curb spending; lawmakers to review as House eyes Wednesday vote
Lithium Has Boomed And This American Stock Is Ready.. (Ad)
Stock market today: Asian markets mostly higher after Biden-McCarthy deal on US debt
PwC Australia sidelines 9 directors as leak of tax information investigated
This NASDAQ Stock Is The Amazon Of Medical Supply (Ad)
North Korea notifies neighboring Japan it plans to launch satellite in coming days
Drought-struck Barcelona quenches thirst with costly desalination
Lithium Has Boomed And This American Stock Is Ready.. (Ad)
Takeaways on debt ceiling: McCarthy's balancing act, Biden's choice and the challenges ahead
Debt ceiling agreement gets thumbs up from business groups, jeers from some on political right
NYSEAMERICAN:VNRX

VolitionRx (VNRX) Stock Forecast, Price & News

$1.45
0.00 (0.00%)
(As of 05/26/2023 08:48 PM ET)
Compare
Today's Range
$1.44
$1.48
50-Day Range
$1.61
$2.60
52-Week Range
$1.31
$2.74
Volume
44,600 shs
Average Volume
179,009 shs
Market Capitalization
$91.61 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.67

VolitionRx MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.75 Rating Score
Upside/​Downside
290.8% Upside
$5.67 Price Target
Short Interest
Bearish
1.63% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.50 out of 5 stars


VNRX stock logo

About VolitionRx (NYSEAMERICAN:VNRX) Stock

VolitionRX Ltd. engages in the development of blood-based cancer tests to help diagnose a range of cancers. Its products include the Nucleosomics platform that identifies and measures nucleosomes in the bloodstream or other bodily fluids. The company was founded on September 24, 1998 and is headquartered in Henderson, NV.

Receive VNRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for VolitionRx and its competitors with MarketBeat's FREE daily newsletter.

VNRX Stock News Headlines

8-K: VOLITIONRX LTD
This NASDAQ Stock Is The Amazon Of Medical Supply
This Little Known Company IS Quickly Becoming The Amazon Of Medical Supply. Learn More Now
VolitionRX Q1 2023 Earnings Preview
VolitionRX's Earnings Outlook
Biden To Unleash "Choke Point" Operation On America?
Biden's disturbing new government program may be worse than Obama's. You are at risk for having your bank account frozen. A former bank regulator is blowing the whistle on Biden's frightening plan to take over your money. Discover the immediate steps you need to take now.
VolitionRx (NYSE:VNRX) Stock Price Up 0.6%
Maxim Group Sticks to Their Buy Rating for VolitionRX (VNRX)
Volition Issues Business Review 2022
VolitionRX Q3 2022 Earnings Preview
Volition Announces Clinical Research Study with Oncovet
See More Headlines
Receive VNRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for VolitionRx and its competitors with MarketBeat's FREE daily newsletter.

VNRX Company Calendar

Last Earnings
3/15/2023
Today
5/29/2023
Next Earnings (Estimated)
8/08/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Diagnostic substances
Sub-Industry
N/A
Sector
Medical
Current Symbol
NYSEAMERICAN:VNRX
Previous Symbol
NYSEMKT:VNRX
CIK
N/A
Employees
65
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$5.67
High Stock Price Forecast
$6.00
Low Stock Price Forecast
$5.00
Forecasted Upside/Downside
+290.8%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.75
Research Coverage
4 Analysts

Profitability

Net Income
$-30,270,000.00
Net Margins
-9,158.31%
Pretax Margin
-9,257.43%
Return on Equity
-15,493.47%

Debt

Sales & Book Value

Annual Sales
$310,000.00
Book Value
($0.05) per share

Miscellaneous

Free Float
53,071,000
Market Cap
$91.61 million
Optionable
Not Optionable
Beta
1.67

Key Executives

  • Cameron John Reynolds
    President, Chief Executive Officer & Director
  • Gaetan Michel
    Chief Operating Officer
  • Terig Hughes
    Chief Financial Officer & Treasurer
  • Jacob Vincent Micallef
    Chief Scientific Officer
  • Mark Eccleston
    Chief Technology Officer













VNRX Stock - Frequently Asked Questions

Should I buy or sell VolitionRx stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for VolitionRx in the last twelve months. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" VNRX shares.
View VNRX analyst ratings
or view top-rated stocks.

What is VolitionRx's stock price forecast for 2023?

4 equities research analysts have issued twelve-month price objectives for VolitionRx's stock. Their VNRX share price forecasts range from $5.00 to $6.00. On average, they anticipate the company's stock price to reach $5.67 in the next year. This suggests a possible upside of 290.8% from the stock's current price.
View analysts price targets for VNRX
or view top-rated stocks among Wall Street analysts.

How have VNRX shares performed in 2023?

VolitionRx's stock was trading at $1.72 on January 1st, 2023. Since then, VNRX stock has decreased by 15.7% and is now trading at $1.45.
View the best growth stocks for 2023 here
.

When is VolitionRx's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 8th 2023.
View our VNRX earnings forecast
.

How were VolitionRx's earnings last quarter?

VolitionRx Limited (NYSEAMERICAN:VNRX) announced its quarterly earnings data on Wednesday, March, 15th. The medical research company reported ($0.13) EPS for the quarter, beating analysts' consensus estimates of ($0.15) by $0.02. The medical research company earned $0.12 million during the quarter, compared to the consensus estimate of $0.06 million. VolitionRx had a negative net margin of 9,158.31% and a negative trailing twelve-month return on equity of 15,493.47%.

What other stocks do shareholders of VolitionRx own?
What is VolitionRx's stock symbol?

VolitionRx trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "VNRX."

Who are VolitionRx's major shareholders?

VolitionRx's stock is owned by many different retail and institutional investors. Top institutional investors include Lagoda Investment Management L.P. (5.98%), BlackRock Inc. (0.87%), Cerity Partners LLC (0.10%), Bank of America Corp DE (0.10%), JPMorgan Chase & Co. (0.06%) and Cubist Systematic Strategies LLC (0.05%). Insiders that own company stock include Cameron John Reynolds, Guy Archibald Innes, Jacob Vincent Micallef, Jason Bradley Md Terrell, Kim Nguyen, Martin Charles Faulkes, Nicholas Plummer and Salvatore Thomas Butera.
View institutional ownership trends
.

How do I buy shares of VolitionRx?

Shares of VNRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is VolitionRx's stock price today?

One share of VNRX stock can currently be purchased for approximately $1.45.

How much money does VolitionRx make?

VolitionRx (NYSEAMERICAN:VNRX) has a market capitalization of $91.61 million and generates $310,000.00 in revenue each year. The medical research company earns $-30,270,000.00 in net income (profit) each year or ($0.56) on an earnings per share basis.

How can I contact VolitionRx?

VolitionRx's mailing address is 13215 BEE CAVE PARKWAY GALLERIA OAKS B SUITE 125, AUSTIN TX, 78738. The official website for the company is www.volitionrx.com. The medical research company can be reached via phone at (646) 650-1351, via email at investorrelations@volition.com, or via fax at 65 32 8172 5651.

This page (NYSEAMERICAN:VNRX) was last updated on 5/29/2023 by MarketBeat.com Staff

My Account -